US HB2620 | 2019-2020 | 116th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 14-8)
Status: Introduced on May 9 2019 - 25% progression, died in committee
Action: 2019-05-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 9 2019 - 25% progression, died in committee
Action: 2019-05-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Requires the Department of Health and Human Services to establish a pilot program that provides for a partial federal guarantee of specified bonds, the sale of which shall finance promising translational vision-impairment research with private investment. The Government Accountability Office must study this program and consider whether similar programs should be established for other areas of biomedical research.
Title
Faster Treatments and Cures for Eye Diseases Act
Sponsors
| Rep. Sanford Bishop [D-GA] | Rep. Cathy McMorris Rodgers [R-WA] | Rep. Gus Bilirakis [R-FL] | Rep. Steve Cohen [D-TN] |
| Rep. Tom O'Halleran [D-AZ] | Rep. Bradley Schneider [D-IL] | Rep. Brian Fitzpatrick [R-PA] | Rep. Kenny Marchant [R-TX] |
| Rep. Eliot Engel [D-NY] | Rep. Pete Olson [R-TX] | Rep. Debbie Wasserman Schultz [D-FL] | Rep. G. Butterfield [D-NC] |
| Rep. Jeff Fortenberry [R-NE] | Rep. Darren Soto [D-FL] | Rep. Jared Huffman [D-CA] | Rep. John Rutherford [R-FL] |
| Rep. Henry Johnson [D-GA] | Rep. Tim Walberg [R-MI] | Rep. Bobby Rush [D-IL] | Rep. Terri Sewell [D-AL] |
| Rep. Mike Levin [D-CA] | Rep. Gregory Meeks [D-NY] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-05-10 | House | Referred to the Subcommittee on Health. |
| 2019-05-09 | House | Referred to the House Committee on Energy and Commerce. |
| 2019-05-09 | House | Introduced in House |
Subjects
Administrative law and regulatory procedures
Congressional oversight
Department of Health and Human Services
Drug therapy
Executive agency funding and structure
Financial services and investments
Genetics
Government information and archives
Government lending and loan guarantees
Government studies and investigations
Health
Health programs administration and funding
Health promotion and preventive care
Health technology, devices, supplies
Hearing, speech, and vision care
Interest, dividends, interest rates
Medical research
Public-private cooperation
Research administration and funding
Research and development
Securities
User charges and fees
Congressional oversight
Department of Health and Human Services
Drug therapy
Executive agency funding and structure
Financial services and investments
Genetics
Government information and archives
Government lending and loan guarantees
Government studies and investigations
Health
Health programs administration and funding
Health promotion and preventive care
Health technology, devices, supplies
Hearing, speech, and vision care
Interest, dividends, interest rates
Medical research
Public-private cooperation
Research administration and funding
Research and development
Securities
User charges and fees
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/2620/all-info |
| Text | https://www.congress.gov/116/bills/hr2620/BILLS-116hr2620ih.pdf |
